NHLBI/NIDA ADMINISTRATIVE SUPPLEMENTS FOR HIV-RELATED RESEARCH Release Date: May 6, 2002 NOTICE: NOT-HL-02-013 National Heart, Lung, and Blood Institute (http://www.nhlbi.nih.gov/) National Institute on Drug Abuse (http://www.nida.nih.gov/) PURPOSE The National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Drug Abuse (NIDA) announce the availability of Administrative Supplements to NHLBI or NIDA grantees to facilitate the sharing of resources and/or the establishment of collaborations for HIV-associated disease research related to drug abuse, cardiovascular, pulmonary, hematological, and sleep disorders. Applicants for the Administrative Supplements must have NHLBI or NIDA-funded grants studying one of the following: 1) cardiovascular, hematological, or pulmonary complications of HIV; 2) other pulmonary infections that frequently complicate HIV, such as tuberculosis or Pneumocystis carinii; or 3) drug abuse in the setting of HIV and related infections. Applicants for Administrative Supplements may collaborate with other investigators to form a consortium in order to share resources and solve emerging medical issues related to HIV-associated cardiopulmonary and hematological complications or drug abuse in the setting of HIV infection. There are major barriers for investigators conducting HIV-related research, such as access of equipment, core facilities and shared resources. Thus, the NHLBI and NIDA will support, through Administrative Supplements, the introduction of specialized resources and equipment in their ongoing research programs. Examples of items for sharing appropriate for this Administrative Supplement program include, but are not limited to 1) reagents, antibodies, tissues, and animal models; 2) specialized equipment; and 3) expertise, such as bioinformatics and computational services. Only existing R01 grants supported by NHLBI or NIDA, that focus on research involving HIV-related cardiovascular, hematological or pulmonary complications and related infectious diseases or drug abuse in the setting of HIV infection with at least one year of support remaining at the time of the supplemental award are eligible for a supplemental award under this notice. The proposed research must be within the scope of the NHLBI or NIDA-funded parent study. Applicants may request one year of support in $25,000 increments up to a maximum request of $75,000 in direct costs. NHLBI intends to commit up to $2,000,000 in FY 2002 and NIDA intends to commit up to $500,000 in FY 2002 to fund up to a total of 20 supplements. This is a one-time announcement. The receipt date for applications for the Administrative Supplements will be June 25, 2002. The anticipated award date will be before September 30, 2002. Requests must be received by the application receipt date; late applications will not be accepted. To apply for an Administrative Supplement, applicants should send an original letter and two copies countersigned by the grantee institution's authorized business official to Dr. Deborah Applebaum-Bowden for grants supported by NHLBI, or to Dr. Jag H. Khalsa for grants supported by NIDA at the address listed below. The letter, limited to 5 single-space typed pages, must include: o An abstract of the proposed use of supplemental funds and the relationship to the goals of the parent grant. o A detailed description of the proposed use of supplemental funds, including technical expertise, resources available, and methodology. o Expected overall impact of the requested supplement on ongoing research. o A budget request with justification for the budget requested, including any equipment, software tools, reagents, animal costs, travel, and plans for technical service and resource sharing. o Current contact information for the principal investigator, including mailing and e-mail address. Although these descriptions should be as concise as possible, sufficient detail must be provided to allow determination of the merit of the requested supplement. Should the specific aims of the parent grant have changed since the original submission, a separate attachment (not included in the 5-page limit) containing the parent grant number, abstract, and current specific aims will need to be included. Acknowledgment of receipt of the supplement letter will be provided by e-mail. If the applicant has not received a response within ten business days, Dr. Deborah Applebaum-Bowden or Dr. Jag H. Khalsa should be contacted. NHLBI and NIDA will consider supplement requests from all eligible applicants. To be eligible for an administrative supplement, the proposed supplement must fall within the scope of the parent grant, and must be complete. Requests will be evaluated by outside scientists with appropriate expertise. The Review Criteria are: o The relationship of the request to the parent grant. o The significance of the potential impact of the supplement on ongoing research and the field. o The demonstrated availability of the resources and expertise necessary for technical service and/or resource sharing. o The appropriateness of the budget and documentation. The applicant(s) will be notified of the funding decision within 3 months of submission. Award decisions will be based upon the criteria provided above, availability of funds, and NHLBI and NIDA programmatic priorities and balance. INQUIRIES Inquiries concerning this notice are strongly encouraged. The opportunity to clarify any issue or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Deborah Applebaum-Bowden, Ph.D. Division of Heart and Vascular Diseases National Heart, Lung and Blood Institute Two Rockledge Center, Rm 10184 6701 Rockledge Dr., MSC 7956 Bethesda, MD 20892-7956 Telephone: (301) 435-0550 Fax: (301) 480-2858 E-mail: applebad@nhlbi.nih.gov Sandra Colombini Hatch, M.D. Division of Lung Diseases National Heart, Lung, and Blood Institute 6701 Rockledge Drive, Suite 10124, MSC 7952 Bethesda, MD 20892-7952 Telephone: (301) 435-0222 FAX: (301) 480-3557 E-mail: hatchs@nhlbi.nih.gov Luiz Barbosa, D.V.M. Division of Blood Diseases and Resources National Heart, Lung, and Blood Institute 6701 Rockledge Drive, Room 10146, MSC 7950 Bethesda, MD 20892-7950 Telephone: (301) 435-0075 FAX: (301) 480-0868 E-mail: BarbosaL@nhlbi.nih.gov Jag H. Khalsa, Ph.D. Center on AIDS and Other Medical Consequences of Drug Abuse (CAMCODA) National Institute on Drug Abuse (NIDA) 6001 Executive Blvd., room 5198, MSC 9593 Bethesda, MD 20892-9593 Telephone: (301) 443-1801 Fax: (301) 594-6566 E-mail: jk98p@nih.gov Direct inquiries regarding fiscal matters to: Raymond L. Zimmerman Grants Operations Branch National Heart, Lung, and Blood Institute 6701 Rockledge Drive, Room 7156, MSC 7926 Bethesda, MD 20892-7926 Telephone: (301) 435-0171 FAX: (301) 480-3310 E-mail: ZimmermR@nhlbi.nih.gov Gary Fleming, J.D., M.A. Grants Management Branch National Institute on Drug Abuse 6001 Executive Blvd., Room 3131, MSC 9541 Bethesda, MD 20892-9541 Telephone: (301) 443-6710 FAX : (301) 594-6847 E-mail: gf6s@nih.gov
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |